Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

- PMLiVE

WHO, WIPO and WTO to hold technical symposium on pandemic preparedness

The event will examine ways to build resilience to be better prepared for future pandemics

- PMLiVE

AstraZeneca receives CHMP recommendations for Imfinzi, Enhertu and Lynparza

The treatments are for use in prostate, biliary tract and advanced gastric cancer

- PMLiVE

CDC shows new BQ.1 and BQ 1.1 Omicron subvariants account for 44% of US COVID-19 cases

The two new variants accounted for over 32% of US cases the prior week

- PMLiVE

New T-cell study demonstrates ‘powerful’ potential for tailored cancer medicine

The results were published in a peer-reviewed paper in Nature

- PMLiVE

Sanofi/Regeneron’s Dupixent receives CHMP recommendation for prurigo nodularis

Two phase 3 trials showed a reduction in itch, skin lesions and health-related quality of life

- PMLiVE

Precision versus personalised medicine

Is there a difference?

Sciterion

Online Learning Portal on the Impetus InSite Platform®

A Customer Story

Impetus Digital

- PMLiVE

Pfizer/BioNTech BA.4/BA.5 COVID-19 booster receives CHMP recommendation for children five to 11 years

If an authorisation is granted, doses of the bivalent booster will be available to all 27 EU member states

- PMLiVE

Sanofi/GSK’s next-generation COVID-19 booster granted EC approval

Two trials compared the immune response induced by VidPrevtyn Beta with approved vaccines

- PMLiVE

Onyx Health Expands with Two New Appointments

Newcastle-based creative agency Onyx Health has continued to grow and expand with the dual appointments of Rosie Thompson as Account Manager and Modupe Ayeni as a Medical Writer

Onyx Health

- PMLiVE

What constitutes a great creative brief?

We asked, you answered, and the results are in… what really does go into a great creative brief?

Page & Page Health

- PMLiVE

ICR calls for further discussions following NICE’s rejection of breast cancer drug

Olaparib has been shown to cut the risk of cancer recurrence and improve survival

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links